Allianz SE Makes New $83,000 Investment in Ionis Pharmaceuticals, Inc. $IONS

Allianz SE purchased a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,100 shares of the company’s stock, valued at approximately $83,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allworth Financial LP grew its stake in Ionis Pharmaceuticals by 231.8% during the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after acquiring an additional 517 shares in the last quarter. Signaturefd LLC lifted its position in shares of Ionis Pharmaceuticals by 45.6% in the first quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock worth $42,000 after purchasing an additional 433 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Ionis Pharmaceuticals by 151.3% during the second quarter. Parallel Advisors LLC now owns 1,872 shares of the company’s stock worth $74,000 after purchasing an additional 1,127 shares during the period. Ancora Advisors LLC purchased a new position in Ionis Pharmaceuticals during the first quarter valued at approximately $60,000. Finally, CWM LLC grew its position in Ionis Pharmaceuticals by 18.7% during the first quarter. CWM LLC now owns 2,435 shares of the company’s stock valued at $73,000 after purchasing an additional 384 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Buying and Selling

In other news, EVP Richard S. Geary sold 89,249 shares of the business’s stock in a transaction on Friday, October 31st. The shares were sold at an average price of $75.11, for a total value of $6,703,492.39. Following the completion of the transaction, the executive vice president owned 59,657 shares of the company’s stock, valued at $4,480,837.27. The trade was a 59.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth L. Hougen sold 49,800 shares of the firm’s stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $65.26, for a total value of $3,249,948.00. Following the sale, the executive vice president directly owned 110,500 shares in the company, valued at $7,211,230. The trade was a 31.07% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 924,789 shares of company stock worth $59,515,499. 2.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on IONS shares. Bank of America lifted their price objective on shares of Ionis Pharmaceuticals from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Tuesday, September 23rd. TD Cowen raised their target price on Ionis Pharmaceuticals from $59.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, October 30th. BMO Capital Markets upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $40.00 to $70.00 in a research note on Wednesday, September 3rd. Wells Fargo & Company increased their price objective on Ionis Pharmaceuticals from $77.00 to $82.00 and gave the company an “overweight” rating in a report on Friday, August 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $84.15.

Ionis Pharmaceuticals Stock Performance

Ionis Pharmaceuticals stock opened at $71.55 on Friday. The firm has a market capitalization of $11.59 billion, a P/E ratio of -42.34 and a beta of 0.33. The stock has a fifty day moving average price of $68.61 and a two-hundred day moving average price of $49.55. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $76.78. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.87 and a quick ratio of 2.86.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 45.29%. The company had revenue of $156.72 million during the quarter, compared to analysts’ expectations of $131.75 million. During the same quarter in the previous year, the company posted ($0.95) earnings per share. Ionis Pharmaceuticals’s quarterly revenue was up 17.2% compared to the same quarter last year. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.